The Experts below are selected from a list of 288 Experts worldwide ranked by ideXlab platform
Germaine Wong - One of the best experts on this subject based on the ideXlab platform.
-
reduced estimated gfr and Cancer Mortality
American Journal of Kidney Diseases, 2014Co-Authors: Jonathan C Craig, Robin M Turner, Jeremy R Chapman, Jie Jin Wang, Paul Mitchell, Germaine WongAbstract:Background Chronic kidney disease is associated with an increased risk of Cancer, but whether reduced kidney function also leads to increased Cancer Mortality is uncertain. The aim of our study was to assess the independent effects of reduced kidney function on the risk of Cancer deaths. Study Design Prospective population-based cohort study. Setting & Participants Participants of the Blue Mountains Eye Study (n=4,077; aged 49-97 years). Predictor Estimated glomerular filtration rate (eGFR). Outcomes Overall and site-specific Cancer Mortality. Results During a median follow-up of 12.8 (IQR, 8.6-15.8) years, 370 Cancer deaths were observed in our study cohort. For every 10-mL/min/1.73m 2 reduction in eGFR, there was an increase in Cancer-specific Mortality of 18% in the fully adjusted model ( P 2 , the adjusted HR for Cancer-specific Mortality for those with eGFR 2 was 1.27 (95% CI, 1.00-1.60; P =0.05). This excess Cancer Mortality varied with site, with the greatest risk for breast and urinary tract Cancer deaths (adjusted HRs of 1.99 [95% CI, 1.05-3.85; P =0.01] and 2.54 [95% CI, 1.02-6.44; P =0.04], respectively). Limitations Residual confounding, such as from unmeasured socioeconomic factors and the potential effects of erythropoiesis-stimulating agents on Cancer deaths, may have occurred. Conclusions eGFR 2 appears to be a significant risk factor for death from Cancer. These effects appear to be site specific, with breast and urinary tract Cancers incurring the greatest risk of death among those with reduced kidney function.
Kirsten M. M. Beyer - One of the best experts on this subject based on the ideXlab platform.
-
Racial disparities of liver Cancer Mortality in Wisconsin
Cancer Causes & Control, 2019Co-Authors: Amin Bemanian, Laura D. Cassidy, Raphael Fraser, Purushottam W. Laud, Kia Saeian, Kirsten M. M. BeyerAbstract:Purpose To calculate tract-level estimates of liver Cancer Mortality in Wisconsin and identify relationships with racial and socioeconomic variables. Methods County-level standardized Mortality ratios (SMRs) of liver Cancer in Wisconsin were calculated using traditional indirect adjustment methods for cases from 2003 to 2012. Tract-level SMRs were calculated using adaptive spatial filtering (ASF). The tract-level SMRs were checked for correlations to a socioeconomic advantage index (SEA) and percent racial composition. Non-spatial and spatial regression analyses with tract-level SMR as the outcome were conducted. Results County-level SMR estimates were shown to mask much of the variance within counties across their tracts. Liver Cancer Mortality was strongly correlated with the percent of Black residents in a census tract and moderately associated with SEA. In the multivariate spatially-adjusted regression analysis, only Percent Black composition remained significantly associated with an increased liver Cancer SMR. Conclusions Using ASF, we developed a high-resolution map of liver Cancer Mortality in Wisconsin. This map provided details on the distribution of liver Cancer that were inaccessible in the county-level map. These tract-level estimates were associated with several racial and socioeconomic variables.
Amin Bemanian - One of the best experts on this subject based on the ideXlab platform.
-
Racial disparities of liver Cancer Mortality in Wisconsin
Cancer Causes & Control, 2019Co-Authors: Amin Bemanian, Laura D. Cassidy, Raphael Fraser, Purushottam W. Laud, Kia Saeian, Kirsten M. M. BeyerAbstract:Purpose To calculate tract-level estimates of liver Cancer Mortality in Wisconsin and identify relationships with racial and socioeconomic variables. Methods County-level standardized Mortality ratios (SMRs) of liver Cancer in Wisconsin were calculated using traditional indirect adjustment methods for cases from 2003 to 2012. Tract-level SMRs were calculated using adaptive spatial filtering (ASF). The tract-level SMRs were checked for correlations to a socioeconomic advantage index (SEA) and percent racial composition. Non-spatial and spatial regression analyses with tract-level SMR as the outcome were conducted. Results County-level SMR estimates were shown to mask much of the variance within counties across their tracts. Liver Cancer Mortality was strongly correlated with the percent of Black residents in a census tract and moderately associated with SEA. In the multivariate spatially-adjusted regression analysis, only Percent Black composition remained significantly associated with an increased liver Cancer SMR. Conclusions Using ASF, we developed a high-resolution map of liver Cancer Mortality in Wisconsin. This map provided details on the distribution of liver Cancer that were inaccessible in the county-level map. These tract-level estimates were associated with several racial and socioeconomic variables.
Frank R. Lichtenberg - One of the best experts on this subject based on the ideXlab platform.
-
Has medical innovation reduced Cancer Mortality
National Bureau of Economic Research, 2020Co-Authors: Frank R. LichtenbergAbstract:I analyze the effects of four types of medical innovation and Cancer incidence on U.S. Cancer Mortality rates during the period 2000-2009, by estimating difference-in-differences models using longitudinal (annual) data on about 60 Cancer sites (breast, colon, etc.). The outcome measure used is not subject to lead-time bias. I control for mean age at diagnosis, the stage distribution of patients at time of diagnosis, and the sex and race of diagnosed patients. Under the assumption that there were no pre‐dated factors that drove both innovation and Mortality and that there would have been parallel trends in Mortality in the absence of innovation, the estimates indicate that there were three major sources of the 13.8% decline of the age-adjusted Cancer Mortality rate during 2000-2009. Drug innovation and imaging innovation are estimated to have reduced the Cancer Mortality rate by 8.0% and 4.0%, respectively. The decline in incidence is estimated to have reduced the Cancer Mortality rate by 1.2%. The social value of the reductions in Cancer Mortality attributable to medical innovations has been enormous, and much greater than the cost of these innovations.
-
Has medical innovation reduced Cancer Mortality
CESifo Economic Studies, 2013Co-Authors: Frank R. LichtenbergAbstract:I analyze the effects of four types of medical innovation and Cancer incidence on US Cancer Mortality rates during the period 2000–2009, by estimating difference-in-differences models using longitudinal (annual) data on ∼60 Cancer sites (breast, colon, etc.). The outcome measure used is not subject to lead-time bias. I control for mean age at diagnosis, the stage distribution of patients at time of diagnosis, and the sex and race of diagnosed patients. Under the assumption that there were no pre-dated factors that drove both innovation and Mortality and that there would have been parallel trends in Mortality in the absence of innovation, the estimates indicate that there were three major sources of the 13.8% decline of the age-adjusted Cancer Mortality rate during 2000–2009. Drug innovation and imaging innovation are estimated to have reduced the Cancer Mortality rate by 8.0 and 4.0%, respectively. The decline in incidence is estimated to have reduced the Cancer Mortality rate by 1.2%. The social value of the reductions in Cancer Mortality attributable to medical innovations has been enormous, and much greater than the cost of these innovations. (JEL codes: C23, J11, I12, O33)
Gonzalo López-abente - One of the best experts on this subject based on the ideXlab platform.
-
Ovarian Cancer Mortality and industrial pollution.
Environmental Pollution, 2015Co-Authors: Javier García-pérez, Virginia Lope, Gonzalo López-abente, Mario González-sánchez, Pablo Fernández-navarroAbstract:Abstract We investigated whether there might be excess ovarian Cancer Mortality among women residing near Spanish industries, according to different categories of industrial groups and toxic substances. An ecologic study was designed to examine ovarian Cancer Mortality at a municipal level (period 1997–2006). Population exposure to pollution was estimated by means of distance from town to facility. Using Poisson regression models, we assessed the relative risk of dying from ovarian Cancer in zones around installations, and analyzed the effect of industrial groups and pollutant substances. Excess ovarian Cancer Mortality was detected in the vicinity of all sectors combined, and, principally, near refineries, fertilizers plants, glass production, paper production, food/beverage sector, waste treatment plants, pharmaceutical industry and ceramic. Insofar as substances were concerned, statistically significant associations were observed for installations releasing metals and polycyclic aromatic chemicals. These results support that residing near industries could be a risk factor for ovarian Cancer Mortality.
-
Cancer Mortality trends in Spain: 1980–2007
Annals of Oncology, 2010Co-Authors: Anna Cabanes, Virginia Lope, Marina Pollán, Beatriz Pérez-gómez, Nuria Aragonés, Enrique Vidal, Gonzalo López-abenteAbstract:Abstract Introduction: Since the 1990s, there has been a downturn in Mortality for specific types of tumour in Spain and other European countries. This article reports on the current situation of Cancer Mortality in Spain, as well as Mortality trends over the period 1980–2007, and provides an overview of Cancer Mortality trends in Europe in recent years. Methods: Data were sourced from the National Statistics Institute (Instituto Nacional de Estadistica – INE) and the World Health Organization Mortality database. Mortality trends were studied using change-point Poisson regression models. Results: All-Cancer Mortality decreased in both sexes from 1980 to 2007, owing to the fact that the tumours responsible for the highest number of deaths registered declining trends from the mid-1990s onwards. In men, Mortality due to stomach and prostate Cancer fell by >3% per annum in the last 10 years of the study period. In women, the largest contributions to the fall in Cancer Mortality were due to breast and colorectal Cancers. In contrast, female Mortality due to smoking-related Cancers rose significantly. Within the European context, Spain's estimated 2005 Mortality rates were intermediate for men and low for women. Conclusion: Cancer control is progressing in the right direction in Spain. Further interventions directed to reduce tobacco-related Cancer Mortality remain a priority, particularly for women.
-
Municipal distribution of ovarian Cancer Mortality in Spain.
BMC Cancer, 2008Co-Authors: Virginia Lope, Javier García-pérez, Marina Pollán, Beatriz Pérez-gómez, Nuria Aragonés, Enrique Vidal, Diana Gómez-barroso, Rebeca Ramis, Anna Cabanes, Gonzalo López-abenteAbstract:Background Spain was the country that registered the greatest increases in ovarian Cancer Mortality in Europe. This study describes the municipal distribution of ovarian Cancer Mortality in Spain using spatial models for small-area analysis.
